ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies

Bibliography

• Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006;25:231-59
   PubMed Web of Science ®Google Scholar
• Kimura Y, Matsuo M, Takahashi K, ATP hydrolysis-dependent multidrug efflux transporter: MDR1/P-glycoprotein. Curr Drug Metab 2004;5:1-10
   PubMed Web of Science ®Google Scholar
• Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 2006;86:849-99
   PubMed Web of Science ®Google Scholar
• Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 2003; 33:(Suppl 2):6-9
   PubMed Web of Science ®Google Scholar
• Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther 2009;328:3-9
   PubMed Web of Science ®Google Scholar
• Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia 2008;56:1711-35
   PubMed Web of Science ®Google Scholar
• Zimmermann C, Gutmann H, Hruz P, Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 2005;33:219-24
   PubMed Web of Science ®Google Scholar
• Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461:237-62
   PubMed Web of Science ®Google Scholar
• Kock K, Grube M, Jedlitschky G, Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet 2007;46:449-70
   PubMed Web of Science ®Google Scholar
• Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34:47-54
   PubMed Web of Science ®Google Scholar
• Oswald S, Grube M, Siegmund W, Kroemer HK. Transporter-mediated uptake into cellular compartments. Xenobiotica 2007;37:1171-95
   PubMed Web of Science ®Google Scholar
• Widmer N, Colombo S, Buclin T, Decosterd LA. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003;102:1142
   PubMed Web of Science ®Google Scholar
• Jones K, Hoggard PG, Sales SD, Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001;15:675-81
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58
   PubMed Web of Science ®Google Scholar
• Bilello JA, Drusano GL. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J Infect Dis 1996;173:1524-6
   PubMed Web of Science ®Google Scholar
• Nascimbeni M, Lamotte C, Peytavin G, Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 1999;43:2629-34
   PubMed Web of Science ®Google Scholar
• Drach D, Zhao S, Drach J, Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-34
   PubMed Web of Science ®Google Scholar
• Ludescher C, Pall G, Irschick EU, Gastl G. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br J Haematol 1998;101:722-7
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992;80:2735-9
   PubMed Web of Science ®Google Scholar
• Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-8
   PubMed Web of Science ®Google Scholar
• Vasquez EM, Petrenko Y, Jacobssen V, An assessment of P-glycoprotein expression and activity in peripheral blood lymphocytes of transplant candidates. Transplant Proc 2005;37:175-7
   PubMed Web of Science ®Google Scholar
• Coon JS, Wang YZ, Bines SD, Multidrug resistance activity in human lymphocytes. Hum Immunol 1991;32:134-40
   PubMed Web of Science ®Google Scholar
• Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest 2003;33:261-7
   PubMed Web of Science ®Google Scholar
• Giraud C, Decleves X, Perrot J, High Levels of P-Glycoprotein Activity in Human Lymphocytes in the First 6 Months of Life. Clin Pharmacol Ther 2009;85:289-95
   PubMed Web of Science ®Google Scholar
• Wilisch A, Noller A, Handgretinger R, Mdr1/P-glycoprotein expression in natural killer (NK) cells enriched from peripheral or umbilical cord blood. Cancer Lett 1993;69:139-48
   PubMed Web of Science ®Google Scholar
• Malorni W, Lucia MB, Rainaldi G, Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica 1998;83:13-20
   PubMedGoogle Scholar
• Egashira M, Kawamata N, Sugimoto K, P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999;93:599-606
   PubMed Web of Science ®Google Scholar
• Janneh O, Owen A, Chandler B, Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005;19:2097-102
   PubMed Web of Science ®Google Scholar
• Dupuis ML, Flego M, Molinari A, Cianfriglia M. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. HIV Med 2003;4:338-45
   PubMedGoogle Scholar
• Oerlemans R, van der Heijden J, Vink J, Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum 2006;54:557-68
   PubMed Web of Science ®Google Scholar
• Trambas C, Wang Z, Cianfriglia M, Woods G. Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. Br J Haematol 2001;114:177-84
   PubMed Web of Science ®Google Scholar
• Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M. Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. Chemotherapy 2003;49:8-16
   PubMed Web of Science ®Google Scholar
• Langmann T, Mauerer R, Zahn A, Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 2003;49:230-8
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2005;20:452-77
   PubMedGoogle Scholar
• Sleasman JW, Leon BH, Aleixo LF, Immunomagnetic selection of purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation. Clin Diagn Lab Immunol 1997;4:653-8
   PubMedGoogle Scholar
• Oselin K, Mrozikiewicz PM, Pahkla R, Roots I. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 2003;71:119-23
   PubMed Web of Science ®Google Scholar
• Legrand O, Perrot JY, Tang R, Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol 1996;94:23-33
   PubMed Web of Science ®Google Scholar
• Laupeze B, Amiot L, Payen L, Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sci 2001;68:1323-31
   PubMed Web of Science ®Google Scholar
• Zhang J, Alston MA, Huang H, Rabin RL. Human T cell cytokine responses are dependent on multidrug resistance protein-1. Int Immunol 2006;18:485-93
   PubMed Web of Science ®Google Scholar
• Moustafa MA, Ogino D, Nishimura M, Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma. Cancer Sci 2004;95:530-6
   PubMed Web of Science ®Google Scholar
• Giraud C, Manceau S, Decleves X, Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes. J Clin Pharmacol 2008;50:226-30
   Web of Science ®Google Scholar
• Drach J, Gsur A, Hamilton G, Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996;88:1747-54
   PubMed Web of Science ®Google Scholar
• Raghu G, Park SW, Roninson IB, Mechetner EB. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 1996;24:1258-64
   PubMed Web of Science ®Google Scholar
• Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Involvement of P-glycoprotein in the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. J Pharm Pharmacol 2005;57:1421-5
   PubMed Web of Science ®Google Scholar
• Frank MH, Denton MD, Alexander SI, Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 2001;166:2451-9
   PubMed Web of Science ®Google Scholar
• Gupta S. P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging 1995;7:19-29
   PubMed Web of Science ®Google Scholar
• Eisenbraun MD, Mosley RL, Teitelbaum DH, Miller RA. Altered development of intestinal intraepithelial lymphocytes in P-glycoprotein-deficient mice. Dev Comp Immunol 2000;24:783-95
   PubMed Web of Science ®Google Scholar
• Markham PN, Coon JS, Chong AS, Gebel HM. Natural killer cell cytotoxicity and the multidrug resistance gene. Transplant Proc 1993;25:96-7
   PubMed Web of Science ®Google Scholar
• Yamashiro T, Watanabe N, Yokoyama KK, Requirement of expression of P-glycoprotein on human natural killer leukemia cells for cell-mediated cytotoxicity. Biochem Pharmacol 1998;55:1385-90
   PubMed Web of Science ®Google Scholar
• Gupta S, Kim CH, Tsuruo T, Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol 1992;12:451-8
   PubMed Web of Science ®Google Scholar
• Chong AS, Markham PN, Gebel HM, Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 1993;36:133-9
   PubMed Web of Science ®Google Scholar
• Gollapudi S, Kim C, Gupta S. P-glycoprotein (encoded by multidrug resistance genes) is not required for interleukin-2 secretion in mice and humans. Genes Immun 2000;1:371-9
   PubMed Web of Science ®Google Scholar
• Eisenbraun MD, Miller RA. mdr1a-encoded P-glycoprotein is not required for peripheral T cell proliferation, cytokine release, or cytotoxic effector function in mice. J Immunol 1999;163:2621-7
   PubMed Web of Science ®Google Scholar
• Liao Z, Cimakasky LM, Hampton R, Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001;17:1009-19
   PubMed Web of Science ®Google Scholar
• Speck RR, Yu XF, Hildreth J, Flexner C. Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002;186:332-40
   PubMed Web of Science ®Google Scholar
• Lee CG, Ramachandra M, Jeang KT, Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J 2000;14:516-22
   PubMed Web of Science ®Google Scholar
• Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-42
   PubMed Web of Science ®Google Scholar
• Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003;55:425-61
   PubMed Web of Science ®Google Scholar
• Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004;1:27-42
   PubMedGoogle Scholar
• Jones K, Bray PG, Khoo SH, P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 2001;15:1353-8
   PubMed Web of Science ®Google Scholar
• Hennessy M, Clarke S, Spiers JP, Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir Ther 2004;9:115-22
   PubMed Web of Science ®Google Scholar
• Meaden ER, Hoggard PG, Newton P, P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002;50:583-8
   PubMed Web of Science ®Google Scholar
• Janneh O, Jones E, Chandler B, Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007;60:987-93
   PubMed Web of Science ®Google Scholar
• Lee CG, Gottesman MM, Cardarelli CO, HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-601
   PubMed Web of Science ®Google Scholar
• Leier I, Jedlitschky G, Buchholz U, The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994;269:27807-10
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Finch RA, Jager D, The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000;103:757-68
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Schuetz JD. Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 2006;46:381-410
   PubMed Web of Science ®Google Scholar
• Lucia MB, Savarino A, Straface E, Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition. J Acquir Immune Defic Syndr 2005;40:257-66
   PubMed Web of Science ®Google Scholar
• Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 2006;27:438-46
   PubMed Web of Science ®Google Scholar
• Marchan R, Hammond CL, Ballatori N. Multidrug resistance-associated protein 1 as a major mediator of basal and apoptotic glutathione release. Biochim Biophys Acta 2008;1778:2413-20
   PubMed Web of Science ®Google Scholar
• Mihm S, Ennen J, Pessara U, Inhibition of HIV-1 replication and NF-kappa B activity by cysteine and cysteine derivatives. AIDS 1991;5:497-503
   PubMed Web of Science ®Google Scholar
• Jorajuria S, Dereuddre-Bosquet N, Becher F, ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther 2004;9:519-28
   PubMed Web of Science ®Google Scholar
• Williams GC, Liu A, Knipp G, Sinko PJ. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 2002;46:3456-62
   PubMed Web of Science ®Google Scholar
• Wang X, Baba M. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother 2005;16:213-6
   PubMedGoogle Scholar
• Borst P, Balzarini J, Ono N, The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004;62:1-7
   PubMed Web of Science ®Google Scholar
• Ameyaw MM, Regateiro F, Li T, MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001;11:217-21
   PubMedGoogle Scholar
• Hoffmeyer S, Burk O, von Richter O, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8
   PubMed Web of Science ®Google Scholar
• Fellay J, Marzolini C, Meaden ER, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-6
   PubMed Web of Science ®Google Scholar
• Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol 2005;528:27-36
   PubMed Web of Science ®Google Scholar
• Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004;5:11-9
   PubMed Web of Science ®Google Scholar
• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33
   PubMed Web of Science ®Google Scholar
• Kim RB, Leake BF, Choo EF, Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99
   PubMed Web of Science ®Google Scholar
• Colombo S, Soranzo N, Rotger M, Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 2005;15:599-608
   PubMed Web of Science ®Google Scholar
• Conrad S, Kauffmann HM, Ito K, Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 2001;46:656-63
   PubMed Web of Science ®Google Scholar
• Conrad S, Kauffmann HM, Ito K, A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 2002;12:321-30
   PubMedGoogle Scholar
• Ito S, Ieiri I, Tanabe M, Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001;11:175-84
   PubMedGoogle Scholar
• Saito S, Iida A, Sekine A, Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J Hum Genet 2002;47:147-71
   PubMed Web of Science ®Google Scholar
• Wang H, Hao B, Zhou K, Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann Hum Genet 2004;68:563-73
   PubMed Web of Science ®Google Scholar
• Letourneau IJ, Deeley RG, Cole SP. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 2005;15:647-57
   PubMed Web of Science ®Google Scholar
• Moriya Y, Nakamura T, Horinouchi M, Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2002;25:1356-9
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang B, Tang K, A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 2005;14:2075-87
   PubMed Web of Science ®Google Scholar
• Oselin K, Mrozikiewicz PM, Gaikovitch E, Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 2003;59:347-50
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006;112:457-73
   PubMed Web of Science ®Google Scholar
• Hirouchi M, Suzuki H, Itoda M, Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res 2004;21:742-8
   PubMed Web of Science ®Google Scholar
• Giessmann T, Modess C, Hecker U, CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004;75:213-22
   PubMed Web of Science ®Google Scholar
• Lang T, Hitzl M, Burk O, Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004;14:155-64
   PubMedGoogle Scholar
• Koshiba S, An R, Saito H, Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica 2008;38:863-88
   PubMed Web of Science ®Google Scholar
• Zamber CP, Lamba JK, Yasuda K, Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003;13:19-28
   PubMedGoogle Scholar
• Imai Y, Nakane M, Kage K, C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1:611-6
   PubMed Web of Science ®Google Scholar
• Morisaki K, Robey RW, Ozvegy-Laczka C, Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005;56:161-72
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72
   PubMed Web of Science ®Google Scholar
• Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003;28:203-28
   PubMed Web of Science ®Google Scholar
• Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006;109:137-61
   PubMed Web of Science ®Google Scholar
• Collett A, Tanianis-Hughes J, Warhurst G. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 2004;68:783-90
   PubMed Web of Science ®Google Scholar
• Jigorel E, Le Vee M, Boursier-Neyret C, Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 2006;34:1756-63
   PubMed Web of Science ®Google Scholar
• van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 2008;36:604-13
   PubMed Web of Science ®Google Scholar
• Greiner B, Eichelbaum M, Fritz P, The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53
   PubMed Web of Science ®Google Scholar
• Schote AB, Turner JD, Schiltz J, Muller CP. Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 2007;44:1436-45
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Heidrich J, Svensson K, Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998;95:12208-13
   PubMed Web of Science ®Google Scholar
• Siest G, Jeannesson E, Marteau JB, Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008;36:182-9
   PubMed Web of Science ®Google Scholar
• Owen A, Chandler B, Back DJ, Khoo SH. Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 2004;9:819-21
   PubMed Web of Science ®Google Scholar
• Becquemont L, Camus M, Eschwege V, Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam Clin Pharmacol 2000;14:519-25
   PubMed Web of Science ®Google Scholar
• Owen A, Goldring C, Morgan P, Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol 2006;62:237-42
   PubMed Web of Science ®Google Scholar
• Lucia MB, Rutella S, Leone G, HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 2001;27:321-30
   PubMed Web of Science ®Google Scholar
• Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999;13:1623-7
   PubMed Web of Science ®Google Scholar
• Choo EF, Leake B, Wandel C, Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655-60
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Fahey JM, Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 2000;14:1287-9
   PubMed Web of Science ®Google Scholar
• Bousquet L, Roucairol C, Hembury A, Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses 2008;24:1147-54
   PubMed Web of Science ®Google Scholar
• Weiss J, Herzog M, Konig S, Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 2009;109:242-50
   PubMed Web of Science ®Google Scholar
• Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002;19:1038-45
   PubMed Web of Science ®Google Scholar
• Yu XQ, Xue CC, Wang G, Zhou SF. Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr Drug Metab 2007;8:787-802
   PubMed Web of Science ®Google Scholar
• van de Water FM, Masereeuw R, Russel FG. Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metab Rev 2005;37:443-71
   PubMed Web of Science ®Google Scholar
• Turriziani O, Gianotti N, Falasca F, Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol 2008;80:766-71
   PubMed Web of Science ®Google Scholar
• Weiss J, Theile D, Ketabi-Kiyanvash N, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007;35:340-4
   PubMed Web of Science ®Google Scholar
• Weiss J, Rose J, Storch CH, Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 2007;59:238-45
   PubMed Web of Science ®Google Scholar
• Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003;22:7496-511
   PubMed Web of Science ®Google Scholar
• Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 2006;6:295-311
   PubMed Web of Science ®Google Scholar
• Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res 2004;21:1284-93
   PubMed Web of Science ®Google Scholar
• Wang H, Unadkat JD, Mao Q. Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res 2008;25:444-52
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou L, Gupta A, Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am J Physiol Endocrinol Metab 2006;290:E798-807
   PubMed Web of Science ®Google Scholar
• Mutoh K, Tsukahara S, Mitsuhashi J, Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 2006;97:1198-204
   PubMed Web of Science ®Google Scholar
• Lindenmaier H, Becker M, Haefeli WE, Weiss J. Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos 2005;33:1576-9
   PubMed Web of Science ®Google Scholar
• Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995;275:1011-8
   PubMed Web of Science ®Google Scholar
• de Zwart L, Scholten M, Monbaliu JG, The ontogeny of drug metabolizing enzymes and transporters in the rat. Reprod Toxicol 2008;26:220-30
   PubMed Web of Science ®Google Scholar
• Salphati L, Benet LZ. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 1998;55:387-95
   PubMed Web of Science ®Google Scholar
• Suzuki T, Zhao YL, Nadai M, Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci 2006;79:455-61
   PubMed Web of Science ®Google Scholar
• Frohlich M, Albermann N, Sauer A, In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 2004;68:2409-16
   PubMed Web of Science ®Google Scholar
• MacLean C, Moenning U, Reichel A, Fricker G. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos 2008;36:1249-54
   PubMed Web of Science ®Google Scholar
• Gutmann H, Hruz P, Zimmermann C, Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 2005;70:695-9
   PubMed Web of Science ®Google Scholar
• Sauerbrey A, Sell W, Steinbach D, Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 2002;118:147-50
   PubMed Web of Science ®Google Scholar
• Warrington JS, Greenblatt DJ, von Moltke LL. The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 2004;309:730-6
   PubMed Web of Science ®Google Scholar
• Gupta S, Gollapudi S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993;13:289-301
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Tsuruo T, Gupta S. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. J Clin Immunol 1997;17:448-54
   PubMed Web of Science ®Google Scholar
• Machado CG, Calado RT, Garcia AB, Falcao RP. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. Braz J Med Biol Res 2003;36:1653-7
   PubMed Web of Science ®Google Scholar
• Pilarski LM, Paine D, McElhaney JE, Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. Am J Hematol 1995;49:323-35
   PubMed Web of Science ®Google Scholar
• Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004;60:97-102
   PubMed Web of Science ®Google Scholar
• Giraud C, Manceau S, Decleves X, Influence of Development, HIV Infection, and Antiretroviral Therapies on the Gene Expression Profiles of ABC Transporters in Human Lymphocytes. J Clin Pharmacol 2009
   PubMed Web of Science ®Google Scholar
• Donnenberg VS, Burckart GJ, Griffith BP, P-glycoprotein (P-gp) is upregulated in peripheral T-cell subsets from solid organ transplant recipients. J Clin Pharmacol 2001;41:1271-9
   PubMed Web of Science ®Google Scholar
• Wirths S, Lanzavecchia A. ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells. Eur J Immunol 2005;35:3433-41
   PubMed Web of Science ®Google Scholar
• Andreana A, Aggarwal S, Gollapudi S, Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1996;12:1457-62
   PubMed Web of Science ®Google Scholar
• Meaden ER, Hoggard PG, Maher B, Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1329-32
   PubMed Web of Science ®Google Scholar
• Lucia MB, Rutella S, Golotta C, Differential induction of P-glycoprotein and MRP by rifamycins in T lymphocytes from HIV-1/tuberculosis co-infected patients. AIDS 2002;16:1563-5
   PubMed Web of Science ®Google Scholar
• Albermann N, Schmitz-Winnenthal FH, Z'Graggen K, Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005;70:949-58
   PubMed Web of Science ®Google Scholar
• McClean S, Hosking LK, Hill BT. Expression of P-glycoprotein-mediated drug resistance in CHO cells surviving a single X-ray dose of 30 Gy. Int J Radiat Biol 1993;63:765-73
   PubMed Web of Science ®Google Scholar
• Gomez-Martinez A, Garcia-Morales P, Carrato A, Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res 2007;5:641-53
   PubMed Web of Science ®Google Scholar
• Yague E, Armesilla AL, Harrison G, P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003;278:10344-52
   PubMed Web of Science ®Google Scholar
• Beck WT, Grogan TM, Willman CL, Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20
   PubMed Web of Science ®Google Scholar
• Taylor BJ, Olson DP, Ivy SP. Detection of P-glycoprotein in cell lines and leukemic blasts: failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cells. Leuk Res 2001;25:1127-35
   PubMed Web of Science ®Google Scholar
• Leith CP, Chen IM, Kopecky KJ, Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. Blood 1995;86:2329-42
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Roelofs EM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991;51:2628-35
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64
   PubMed Web of Science ®Google Scholar
• Rao VV, Anthony DC, Piwnica-Worms D. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J Histochem Cytochem 1995;43:1187-92
   PubMed Web of Science ®Google Scholar
• Lucia MB, Rutella S, Leone G, In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr 2002;30:369-78
   PubMed Web of Science ®Google Scholar
• Meaden ER, Hoggard PG, Khoo SH, Back DJ. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002;262:159-65
   PubMed Web of Science ®Google Scholar
• Daoud R, Kast C, Gros P, Georges E. Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). Biochemistry 2000;39:15344-52
   PubMed Web of Science ®Google Scholar
• Minderman H, Vanhoefer U, Toth K, DiOC2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 1996;25:14-20
   PubMedGoogle Scholar
• Vasconcelos FC, Cavalcanti GB Jr, Silva KL, Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res 2007;31:445-54
   PubMed Web of Science ®Google Scholar
• van der Sandt IC, Vos CM, Nabulsi L, Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier. AIDS 2001;15:483-91
   PubMed Web of Science ®Google Scholar
• Morimoto K, Nakakariya M, Shirasaka Y, Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein. Drug Metab Dispos 2008;36:6-9
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Connelly MC, Sun D, MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-51
   PubMed Web of Science ®Google Scholar
• Marchetti S, de Vries NA, Buckle T, Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008;7:2280-7
   PubMed Web of Science ®Google Scholar
• Huisman MT, Smit JW, Crommentuyn KM, Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002;16:2295-301
   PubMed Web of Science ®Google Scholar
• Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 2007;453:643-59
   PubMed Web of Science ®Google Scholar
• Reid G, Wielinga P, Zelcer N, Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003;63:1094-103
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, Initial sequencing and analysis of the human genome. Nature 2001;409:860-921
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000;275:30069-74
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Boersma AW, Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940-2
   PubMed Web of Science ®Google Scholar
• Goto M, Masuda S, Saito H, C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002;12:451-7
   PubMedGoogle Scholar
• Siegmund W, Ludwig K, Giessmann T, The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002;72:572-83
   PubMed Web of Science ®Google Scholar
• Tanabe M, Ieiri I, Nagata N, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-43
   PubMed Web of Science ®Google Scholar
• Illmer T, Schuler US, Thiede C, MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955-62
   PubMed Web of Science ®Google Scholar
• Oselin K, Gerloff T, Mrozikiewicz PM, MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol 2003;17:463-9
   PubMed Web of Science ®Google Scholar
• Siegsmund M, Brinkmann U, Schaffeler E, Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13:1847-54
   PubMed Web of Science ®Google Scholar
• Hitzl M, Drescher S, van der Kuip H, The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001;11:293-8
   PubMedGoogle Scholar
• Storch CH, Theile D, Lindenmaier H, Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007;73:1573-81
   PubMed Web of Science ®Google Scholar
• Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009;37:359-65
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Sodani K, Wang SR, Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009;78:153-61
   PubMed Web of Science ®Google Scholar
• Fox E, Bates SE. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 2007;7:447-59
   PubMed Web of Science ®Google Scholar
• Chandler B, Almond L, Ford J, The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 2003;33:551-6
   PubMed Web of Science ®Google Scholar
• Lombardo L, Pellitteri R, Balazy M, Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res 2008;5:82-92
   PubMed Web of Science ®Google Scholar
• Klokouzas A, Barrand MA, Hladky SB. Effects of clotrimazole on transport mediated by multidrug resistance associated protein 1 (MRP1) in human erythrocytes and tumour cells. Eur J Biochem 2001;268:6569-77
   PubMedGoogle Scholar
• Kuhnle M, Egger M, Muller C, Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009;52:1190-7
   PubMed Web of Science ®Google Scholar
• Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005;7:E118-33
   PubMed Web of Science ®Google Scholar
• Gupta A, Zhang Y, Unadkat JD, Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004;310:334-41
   PubMed Web of Science ®Google Scholar